



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/775,869	(02/10/2004	Ekaterina Dadachova	96700/845	1864	
1912	7590	11/30/2005		EXAM	EXAMINER	
AMSTER,	ROTHST	EIN & EBENSTE	FETTEROLF,	FETTEROLF, BRANDON J		
90 PARK AVENUE NEW YORK, NY 10016				ART UNIT	PAPER NUMBER	
NEW TOIG	Tell Tolds, III Tollo			1642		

DATE MAILED: 11/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/775,869	DADACHOVA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Brandon J. Fetterolf, PhD	1642				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE]. ety filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
Responsive to communication(s) filed on This action is FINAL. 2b)⊠ This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro					
Disposition of Claims						
4) Claim(s) <u>1-37</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>1-37</u> are subject to restriction and/or expending the application.	vn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	atent Application (PTO-152)				

Dadachova et al.

DETAILED ACTION

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-19, 24-33 and 35-37 as specifically drawn to a method of treating and/or imaging a tumor in a subject comprising administering an amount of a radiolabelled antibody effective to treat and/or image said tumor, classified in class 424, subclass 1.49 and 138.1.
- II. Claims 5, 7-11, 15-16, 20-23, 25 and 37, as specifically drawn to a method of imaging a tumor in a subject comprising administering an amount of a radiolabelled <u>peptide</u> effective to image said tumor, classified in class 424, subclass 1.69.

The inventions are distinct, each from the other because of the following reasons:

The inventions of Groups I-II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the specification does not disclose that their methods would be used together. The method of treating and/or imaging a tumor in a subject comprising administering an amount of a radiolabelled antibody effective to treat and/or image said tumor (Group I) and the method of imaging a tumor in a subject comprising administering an amount of a radiolabelled peptide effective to image said tumor (Group II) are unrelated as they utilize different products which demonstrates that each method has a different mode of operation. Each invention performs this function using structurally and functionally divergent material. Therefore, each method is divergent in materials and steps. For these reasons the inventions of Groups I-II are patentably distinct.

Furthermore, the distinct steps and products require separate and distinct searches. The inventions of Groups I-II have a separate status in the art as shown by their different classifications. As such, it would be burdensome to search the inventions of Groups I-II.

Because the inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification, and the search required for each group is not required for other groups because each group requires a different non-patent literature search due to each group comprising different products and/or method steps, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brandon J. Fetterolf, PhD whose telephone number is (571)-272-2919. The examiner can normally be reached on Monday through Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeff Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Brandon J Fetterolf, PhD Examiner Art Unit 1642

BF

JEFFREY SIEW
SUPERVISORY PATENT EXAMINER
1//27/05